Home / NERV : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does NERV make money? Does NERV have pricing power? What's the Earnings Whisper? Will NERV profit more as the business scales? What is NERV's management track record? Is NERV's current price justified?

Minerva Neurosciences, Inc.

$4.09 +$0.17 (+4.34%)

NASDAQ · 14 Sep 2026 15:42 UTC

Previous Close

$4.15

Day Range

$3.98$4.38

Year Range

$1.93$12.46

Market Cap

190.55M

AVG Volume

217.84K

Trailing/Forward PE

-0.14/-

PEG ratio

Dividend Yield

Next Earnings Date

2026-11-04

Primary Exchange

NASDAQ

Revenue (USD)

NERV Revenue (USD) by year
Period	Revenue (USD)
2025	0
2024	0
2023	0
2022	0
2021	0
2020	41.18M
2019	0
2018	0
2017	0
2016	0

Net Income (USD)

NERV Net Income (USD) by year
Period	Net Income (USD)
2025	-293.42M
2024	1.44M
2023	-30.01M
2022	-32.11M
2021	-49.91M
2020	1.94M
2019	-72.18M
2018	-50.17M
2017	-31.52M
2016	-31.05M

Operating Income (USD)

NERV Operating Income (USD) by year
Period	Operating Income (USD)
2025	-15.1M
2024	-21.85M
2023	-23.12M
2022	-25.23M
2021	-45.37M
2020	1.85M
2019	-56.87M
2018	-51.73M
2017	-41.17M
2016	-30.19M

EBITDA (USD)

NERV EBITDA (USD) by year
Period	EBITDA (USD)
2025	-293.42M
2024	6.02M
2023	-21.69M
2022	-24.69M
2021	-45.28M
2020	2.1M
2019	-75.51M
2018	-50.04M
2017	-40.27M
2016	-30M

Cash Flows (USD)

NERV Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-9.44M
2024	-19.55M
2023	-14.78M
2022	-24.66M
2021	-24.6M
2020	-33.82M
2019	-43.43M
2018	-41.94M
2017	3.09M
2016	-25.69M

EPS (USD)

NERV EPS (USD) by year
Period	EPS (USD)
2025	-26.8
2024	0.19
2023	-4.65
2022	-6.32
2021	-9.34
2020	0.41
2019	-14.82
2018	-10.34
2017	-6.71
2016	-7.83

Expenses (USD)

NERV Expenses (USD) by year
Period	Expenses (USD)
2025	15.1M
2024	21.85M
2023	23.12M
2022	25.23M
2021	45.37M
2020	39.33M
2019	75.86M
2018	51.73M
2017	41.17M
2016	30.19M

Cash & Debt (USD)

NERV Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	82.3M
2024	21.36M
2023	40.91M
2022	36.09M
2021	60.76M
2020	25.36M
2019	45.85M
2018	88M
2017	128.16M
2016	82.98M

Debt ratios

NERV Debt ratios by year
Period	Debt ratios
2025	0.25
2024	0.25
2023	0.46
2022	0.25
2021	0.36
2020	0.15
2019	0.23
2018	0.6

Margins

NERV Margins by year
Period	Margins
2020	100%

Return on Capital

NERV Return on Capital by year
Period	Return on Capital
2025	208.47%
2024	-5.6%
2023	105.44%
2022	160.35%
2021	-625.73%
2020	3.68%
2019	-259.84%
2018	-55.58%
2017	-23.95%
2016	-29.29%

Shares Outstanding

NERV Shares Outstanding by year
Period	Shares Outstanding
2025	11.12M
2024	7.57M
2023	7.57M
2022	5.34M
2021	5.34M
2020	5.24M
2019	4.88M
2018	4.86M
2017	4.84M
2016	4.36M

Book Value Per Share (USD)

NERV Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	-12.66
2024	-3.39
2023	-3.76
2022	-3.75
2021	1.49
2020	10.05
2019	5.69
2018	18.57
2017	27.19
2016	24.31

Total Assets (USD)

NERV Total Assets (USD) by year
Period	Total Assets (USD)
2025	97.97M
2024	37.14M
2023	56.9M
2022	55.09M
2021	77.12M
2020	57.63M
2019	77.5M
2018	139.14M
2017	183.7M
2016	132.94M

Employee Count

NERV Employee Count by year
Period	Employee Count
2025	7
2024	8
2023	9
2022	9
2021	9
2020	11
2019	13
2018	13
2017	12
2016	11

PE Ratio

NERV PE Ratio by year
Period	PE Ratio
Oct 25	2.83
Oct 25	3.17
Oct 25	1.68
Oct 25	1.58
Oct 25	1.42
Sep 25	1.43
Sep 25	1.37
Sep 25	1.47
Sep 25	1.58
Aug 25	1.59
Aug 25	1.64
Aug 25	1.52
Aug 25	2.13
Aug 25	2.31
Jul 25	2.58
Jul 25	2.41
Jul 25	2.03
Jul 25	2
Jun 25	2.15
Jun 25	2.14
Jun 25	2.18
Jun 25	2.23
May 25	1.86
May 25	1.77
May 25	1.82
May 25	8.47
May 25	8.94
Apr 25	9.26
Apr 25	8.42
Apr 25	7.63
Apr 25	7.21
Mar 25	9.52
Mar 25	9.47
Mar 25	8.1
Mar 25	8.63
Feb 25	8.78
Jul 21	14.87
Jul 21	15.68
Jul 21	15.6
Jul 21	18.18
Jul 21	18.75
Jun 21	19.96
Jun 21	21.25
Jun 21	23.43
Jun 21	23.43
May 21	23.84
May 21	25.13
May 21	23.68
May 21	48.82
Apr 21	51.42
Apr 21	54.66
Apr 21	54.87
Apr 21	57.68
Apr 21	64.16
Mar 21	63.08
Mar 21	65.89
Mar 21	72.16

Free Cash Flow Yield

NERV Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-9710.77%
Sep 26	-9097%
Aug 26	-8326.39%
Aug 26	-8326.39%
Aug 26	-8799.06%
Aug 26	-9437.87%
Jul 26	-3111.52%
Jul 26	-3065.31%
Jul 26	-2900.2%
Jul 26	-2623.69%
Jul 26	-2428.2%
Jun 26	-2833.83%
Jun 26	-2770.43%
Jun 26	-2745.86%
Jun 26	-2496.74%
May 26	-2522.17%
May 26	-2354.34%
May 26	-2376.94%
May 26	-2106.09%
May 25	-160.43%
May 25	-151.94%
Apr 25	-146.76%
Apr 25	-161.44%
Apr 25	-178.14%
Apr 25	-188.54%
Mar 25	-142.71%
Mar 25	-143.5%
Mar 25	-167.73%
Mar 25	-157.5%
Feb 25	-154.67%
Feb 25	-147.91%
Feb 25	-136.65%
Feb 25	-121.26%
Jan 25	-116.53%
Jan 25	-124.63%
Jan 25	-120.71%
Jan 25	-124.05%
Jan 25	-118.07%
Dec 24	-119.11%
Dec 24	-124.63%
Dec 24	-121.81%
Dec 24	-119.11%
Nov 24	-119.11%
Nov 24	-120.18%
Nov 24	-122.36%
Nov 24	-115.04%
Nov 24	-105.03%
Oct 24	-112.78%
Oct 24	-109.64%
Oct 24	-105.44%
Oct 24	-105.03%
Sep 24	-101.92%
Sep 24	-97.58%
Sep 24	-93.28%
Sep 24	-105.44%
Aug 24	-100.43%
Aug 24	-104.63%
Aug 24	-107.92%
Aug 24	-95.55%
Aug 24	-94.59%
Jul 24	-89.65%
Jul 24	-87.36%
Jul 24	-80.92%
Jul 24	-88.49%
Jun 24	-86%
Jun 24	-79.75%
Jun 24	-82.38%
Jun 24	-85.19%
May 24	-107.58%
May 24	-112.43%
May 24	-108.86%
May 24	-114.78%
May 24	-115.75%
Apr 24	-80.05%
Apr 24	-78.76%
Apr 24	-78.13%
Apr 24	-76.9%
Mar 24	-75.71%
Mar 24	-73.16%
Mar 24	-70.01%
Mar 24	-69.76%
Mar 24	-74.27%
Feb 24	-28.43%
Feb 24	-20.34%
Feb 24	-16.52%
Feb 24	-18.08%
Jan 24	-20.97%
Jan 24	-22.67%
Jan 24	-22.91%
Jan 24	-27.53%
Dec 23	-27.75%
Dec 23	-24.96%
Dec 23	-26.46%
Dec 23	-27.09%
Dec 23	-23.54%
Nov 23	-33.53%
Nov 23	-32.7%
Nov 23	-41.63%
Nov 23	-58.11%
Oct 23	-76.24%

Price to Sales

NERV Price to Sales by year
Period	Price to Sales
Jul 21	1.91
Jul 21	2.01
Jul 21	2
Jul 21	2.33
Jul 21	2.41
Jun 21	2.56
Jun 21	2.73
Jun 21	3.01
Jun 21	3.01
May 21	3.06
May 21	3.23
May 21	3.04
May 21	2.3
Apr 21	2.42
Apr 21	2.58
Apr 21	2.59
Apr 21	2.72
Apr 21	3.02
Mar 21	2.97
Mar 21	3.11
Mar 21	3.4
Mar 21	2.91
Feb 21	3.16
Feb 21	3.65
Feb 21	3.58
Feb 21	3.47
Jan 21	3.25
Jan 21	3.34
Jan 21	2.76
Jan 21	2.63
Dec 20	2.38
Dec 20	2.5
Dec 20	2.63
Dec 20	2.66
Dec 20	2.79
Nov 20	4.08
Nov 20	3.75
Nov 20	3.62
Nov 20	3.51
Oct 20	3.08
Oct 20	3.15
Oct 20	3.18
Oct 20	3.35
Oct 20	3.01
Sep 20	3.05
Sep 20	3.42
Sep 20	2.75
Sep 20	2.8
Aug 20	3.05
Aug 20	3.08
Aug 20	3.25
Aug 20	3.44

EV/EBITDA

NERV EV/EBITDA by year
Period	EV/EBITDA
Oct 25	1.47
Oct 25	1.81
Oct 25	0.32
Oct 25	0.23
Oct 25	0.06
Sep 25	0.07
Sep 25	0.01
Sep 25	0.11
Sep 25	0.23
Aug 25	0.23
Aug 25	0.29
Aug 25	0.16
Aug 25	-0.46
Aug 25	-0.33
Jul 25	-0.14
Jul 25	-0.26
Jul 25	-0.53
Jul 25	-0.56
Jun 25	-0.44
Jun 25	-0.45
Jun 25	-0.43
Jun 25	-0.39
May 25	-0.66
May 25	-0.73
May 25	-0.69
May 25	-1.52
May 25	-1.41
Apr 25	-1.33
Apr 25	-1.54
Apr 25	-1.72
Apr 25	-1.82
Mar 25	-1.27
Mar 25	-1.28
Mar 25	-1.61
Mar 25	-1.49
Feb 25	-1.45
Feb 25	-3.68
Feb 25	-3.35
Feb 25	-2.8
Jan 25	-2.61
Jan 25	-2.93
Jan 25	-2.78
Jan 25	-2.91
Jan 25	-2.67
Dec 24	-2.72
Dec 24	-2.93
Dec 24	-2.82
Dec 24	-2.72
Nov 24	-2.72
Nov 24	-2.76
Nov 24	-2.85
Nov 24	-2.54
Jul 21	-0.22
Jul 21	0.42
Jul 21	0.35
Jul 21	2.38
Jul 21	2.82
Jun 21	3.77
Jun 21	4.79
Jun 21	6.5
Jun 21	6.5
May 21	6.81
May 21	7.83
May 21	6.69
May 21	33.09
Apr 21	35.49
Apr 21	38.48
Apr 21	38.68
Apr 21	41.28
Apr 21	47.26
Mar 21	46.27
Mar 21	48.86
Mar 21	54.65

Price/Operating Cashflow

NERV Price/Operating Cashflow by year
Period	Price/Operating Cashflow
Apr 18	80.44
Apr 18	90.14
Apr 18	86.38
Apr 18	85.13
Mar 18	78.24
Mar 18	80.12
Mar 18	78.87
Mar 18	76.39
Mar 18	69.09
Feb 18	73.74
Feb 18	72.41
Feb 18	73.74
Feb 18	82.37
Jan 18	87.69
Jan 18	90.34
Jan 18	83.04
Jan 18	79.72
Dec 17	80.38
Dec 17	80.38
Dec 17	79.05
Dec 17	75.73
Dec 17	73.74
Nov 17	71.08
Nov 17	69.09
Nov 17	69.09

Price to Book

NERV Price to Book by year
Period	Price to Book
Apr 22	2.73
Apr 22	3.54
Apr 22	4.17
Apr 22	4.36
Apr 22	4.66
Mar 22	4.34
Mar 22	4.23
Mar 22	3.7
Mar 22	3.59
Feb 22	1.04
Feb 22	1.13
Feb 22	1.11
Feb 22	1.14
Jan 22	1.1
Jan 22	1.28
Jan 22	1.27
Jan 22	1.29
Dec 21	1.22
Dec 21	1.47
Dec 21	1.41
Dec 21	1.38
Dec 21	1.41
Nov 21	1.61
Nov 21	1.7
Nov 21	1.99
Nov 21	1.59
Oct 21	1.65
Oct 21	1.5
Oct 21	1.59
Oct 21	1.69
Oct 21	1.87
Sep 21	2.41
Sep 21	2.01
Sep 21	1.97
Sep 21	2.11
Aug 21	2.23
Aug 21	2.16
Aug 21	2
Aug 21	2.16
Jul 21	1.73
Jul 21	1.83
Jul 21	1.82
Jul 21	2.12
Jul 21	2.18
Jun 21	2.33
Jun 21	2.48
Jun 21	2.73
Jun 21	2.73
May 21	2.78
May 21	2.93
May 21	2.76
May 21	1.8
Apr 21	1.89
Apr 21	2.01
Apr 21	2.02
Apr 21	2.13
Apr 21	2.36
Mar 21	2.32
Mar 21	2.43
Mar 21	2.66
Mar 21	2.07
Feb 21	2.24
Feb 21	2.59
Feb 21	2.54
Feb 21	2.46
Jan 21	2.3
Jan 21	2.37
Jan 21	1.96
Jan 21	1.86
Dec 20	1.69
Dec 20	1.78
Dec 20	1.86
Dec 20	1.89
Dec 20	1.98
Nov 20	2.9
Nov 20	2.66
Nov 20	2.57
Nov 20	2.49
Oct 20	2.23
Oct 20	2.28
Oct 20	2.3
Oct 20	2.42
Oct 20	2.18
Sep 20	2.2
Sep 20	2.48
Sep 20	1.99
Sep 20	2.02
Aug 20	2.2
Aug 20	2.23
Aug 20	2.35
Aug 20	2.49
Jul 20	7.33
Jul 20	7.49
Jul 20	7.58
Jul 20	7.17
Jul 20	7.49
Jun 20	7.36
Jun 20	7.43
Jun 20	7.17
Jun 20	8.25

No video analysis for this stock yet. Request one from our team.

News: NERV

globenewswire.com · 28 Aug 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.

defenseworld.net · 17 Aug 2026

Analysts Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.50

Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) has been assigned an average rating of "Reduce" from the four brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and one has given a buy recommendation to the company.

globenewswire.com · 7 Aug 2026

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported financial and business updates for the second quarter ended June 30, 2026.